Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system

British Journal of Clinical Pharmacology

Volumn 48, Issue 4, 1999, Pages 594-604

  Buchwalder Csajka, C ^a   Buclin, T ^a   Brunner, H R ^a   Biollaz, J ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin; Angiotensin receptor antagonists; Inhibitors; Non linear mixed effect model; Pharmacodynamics

Indexed keywords

5 METHYL 7 PROPYL 8 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDIN 2(3H) ONE; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; CILEXEDIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FORASARTAN; LOSARTAN; LRB 081; N [[4' [(2 ETHYL 5,7 DIMETHYL 3H IMIDAZO[4,5 B]PYRIDIN 3 YL)METHYL] 2 BIPHENYLYL]SULFONYL]BENZAMIDE; OLMESARTAN; RENIN; TAK 536; TASOSARTAN; TEMOCAPRIL; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; META ANALYSIS; METHODOLOGY; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROVOCATION TEST; REGRESSION ANALYSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CLINICAL TRIALS, PHASE I; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, ANGIOTENSIN; REGRESSION ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS;

EID: 0032884456     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00050.x     Document Type: Article

References (47)

1. 1 Brunner HR, Laragh JH. Saralasin in human hypertension: the early experience. Kidney Int 1979; 15: S36-S43.
2. 2 Ferguson RK, Turini GA, Brunner HR, Gavras H. A specific active inhibitor of angiotensin-converting enzyme in man. Lancet 1977; i: 775-778.
3. 8 angiotensin II for understanding and treatment of high blood pressure. Lancet 1973; ii: 1045-1048.
4. 4 Waeber B, Nussberger J, Brunner HR, The renin-angiotensin system: role in experimental and human hypertension. In Handbook of Hypertension: Pathophysiology of Hypertension - Regulatory Mechanisms, Elsevier Science Publishers BV. eds. Zanchetti A, Tarazi RC, 1986: 489-519.
5. 5 Burnier M, Brunner HR. Angiotensin II receptor antagonists-antihypertensive agents. Exp Opin Invest Drugs 1997; 6: 489-500.
6. 6 Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997; 32: 1-29.
7. 7 Brunner HR, Waeber B, Nussberger J. Does pharmacological profiling of a new drug in normotensive volunteers provide a useful guideline to antihypertensive therapy? Hypertension 1983; 5: 101-107.
8. 8 Brunner HR, Nussberger J, Waeber B. Dose-response relationships of ACE inhibitors and angiotensin II blockers. European Heart Journal 1994; 15: 123-128.
9. 9 Buclin T. Buchwalder Csajka C, Brunner HR, Biollaz J. Evaluation of noninvasive blood pressure recording by photoplethysmography in clinical studies using angiotensin challenges. Br J Clin Pharmacol 1999; 48; 586-593.
10. 10 Christen Y, Waeber B, Nussberger J, Brunner HR. Noninvasive blood pressure monitoring at the finger for studying short lasting pressor responses in man. J Clin Pharmacol 1990; 30: 711-714.
11. 11 Rousso P, Buclin T, Nussberger J, Brunner-Ferber F, Brunner HR, Biollaz J. Effects of MDL, 100, 240 a dual inhibitor of angiotensin - converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiotensin I, angiotensin II, challenges in healthy volunteers. J Cardiovasc Pharmacol 1998; 31: 408-417.
12. 12 Erb KA, Essig J, Breithaupt K, Belz GG. Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. Drugs 1991; 41: 11-17.
13. 13 Wellstein A, Essig J, Belz GG. Inhibition of angiotensin I response by cilazapril and its time course in normal volunteers. Clin Pharmacol Ther 1987; 41: 639-644.
14. 14 Essig G, Belz GG, Wellstein A. The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril. Br J Clin Pharmacol 1989; 27: 217S-223S.
15. 15 Biollaz J, Burnier M, Turini GA, et al. Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I. Clin Pharmacol Ther 1981; 29: 665-670.
16. 16 Burnier M, Biollaz J, Brunner HR, Turini GA, Gavras H. Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril. Am J Cardiol 1982; 49: 1550-1551.
17. 17 Given BD, Taylor T, Hollenberg NK, Williams GH. Duration of action and short term hormonal responses to enalapril (MK 421) in normal subjects. J Cardiovasc Pharmacol 1984; 6: 436-441.
18. 18 Jacot des Combes BJ, Turini GA, Brunner HR, Porchet M, Chen DS, Sen SB. CGS 13945: a new orally active angiotensin-converting enzyme inhibitor in normal volunteers. J Cardiovasc Pharmacol 1983; 5: 511-516.
19. 19 Schaller MD, Brunner DB, Nussberger J, et al. A potent converting enzyme inhibitor CGS 13928C. Drug profile in normal volunteers. Eur J Clin Pharmacol 1984; 26: 419-424.
20. 20 Belz G, Essig J, Wellstein A. Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril. J Cardiovasc Pharmacol 1987; 9: 219-244.
21. 21 Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertension 1994; 2191 (Abstract).
22. 22 Steinhäuslin F, Buclin T, Bouissou P, et al. Angiotensin II (AII) blockade effect of ANA-756 in normal volunteers. Clin Pharmacol Ther 1995; 55: 205.
23. 23 Buclin T, Biollaz J, Küng S, et al. Tolerability, pharmacokinetics and pharmacodynamics of the angiotensin II (Ang II) antagonist TAK 536 in healthy volunteers. Clin Pharmacol Ther 1995; 57: 204.
24. 24 Inglessis N, Nussberger J, Hagmann M, et al. Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I. J Cardiovasc Pharmacol 1995; 25: 986-993.
25. 25 Noël B, Del Re G, Capone P, Brunner HR, Nussberger J. Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. J Cardiovasc Pharmacol 1996; 28: 252-258.
26. 26 Delacrétaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995; 25: 14-21.
27. 27 Müller P, Cohen T, De Gasparo M, Sioufi A, Racine-Poon A, Howald H. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-245.
28. 28 Morgan JM, Palmisano M, Piraino A, et al. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Clin Pharmacol Ther 1997; 61: 35-44.
29. 29 Harb G, Morgan J, Prasad P, et al. The pressor inhibitory effect of angiotensin-II antagonist (Valsartan, CGP 48933) on angiotensin-II infusions in healthy subjects. J Invest Med 1995; 43: 239.
30. 30 Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther 1992; 51: 513-521.
31. 31 Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: Inhibition of pressor response to exogenous angiotensin I and II. Circulation 1991; 83: 1333-1342.
32. 32 Hagmann M, Nussberger J, Naudin RB, et al. SC-52458, a new orally active angiotensin II receptor antagonist; inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers. J Cardiovasc Pharmacol 1997; 29: 444-450.
33. 33 Rolan P. The contribution of clinical pharmacology surrogates and models to drug development - a critical appraisal. Br J Clin Pharmacol 1997; 44: 219-225.
34. 34 Sheiner LB. The intellectual health of clinical drug evaluation. Clin Pharmacol Ther 1991; 50: 4-9.
35. 35 MacFadyen RJ, Meredith PA, Elliott HL. Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1993; 25: 274-282.
36. 36 Donnelly R, Meredith PA, Elliott HI. The description and prediction of antihypertensive drug response: an individualised approach. Br J Clin Pharmacol 1991; 31: 627-634.
37. 37 Burnier M, Buclin T, Biollaz J, Nussberger J, Waeber B, Brunner HR. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers. Kidney Int 1996; 49: 24-29.
38. 38 Donnelly R, Meredith PA, Elliott HI., Reid JL. Kinetic-dynamic relations and individual responses to enalapril. Hypertension 1990; 15: 301-309.
39. 39 Burnier M, Turini GA, Brunner HR, et al. RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers. Br J Clin Pharmacol 1981; 12: 893-899.
40. 40 Bussien JP, Nussberger J, Porchet M, et al. The effect of the converting enzyme inhibitor HOE 498 on the renin angiotensin system or normal volunteers. Naunyn Schmiedebergs Arch Pharmacol 1985; 329: 63-69.
41. 41 Buclin T, Rousso P, Nussberger J, et al. Effects of MD1.100, 240 on the response to angiotensin I and II challenges in healthy volunteers. Clin Pharmacol Ther 1997 61: 208.
42. 42 Goldberg MR, Lo M-W, Christ DD, et al. DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan. Clin Pharmacol Ther 1997; 61: 59-69.
43. 43 Ogihara T, Nagano M, Mikami H, et al. Effects of the angiotensin II, TCV-116, on blood pressure and the renin-angiotensin system in healthy subjects. Clin Ther 1994; 16: 74-86.
44. 44 Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-902.
45. 45 Naudin R, Hagmann M, Nussberger J, Brunner H. Oral administration of SC-52458, a specific angiotensin II receptor antagonist, to healthy male volunteers. J Hypertension 1994; 12: S93.
46. 46 Hagmann M, Delacrétaz E, Nussberger J, et al. Clinical and hormonal assessment of SC-52458, a new orally active angiotensin II receptor antagonist in normontensive volunteers. Am J Hypertension 1994; 7 (4): 57A.
47. 47 Hecht A, Heinzel G, Stangier J, Duong DN, Su CAPF. PK/PD study of BIBR 363 CL2, a long-lasting angiotensin II antagonist. Prediction of optimal doses for multiple dosing from single dose results. Clin Pharmacol Ther 1996; 59: 163.